

## Supplementary information

### Bioassay-guided isolation of anti-inflammatory constituents from the subaerial parts of *Cyperus articulatus* (Cyperaceae)

Domenic Mittas <sup>1</sup>, Monizi Mawunu <sup>2</sup>, Giorgia Magliocca <sup>3</sup>, Thea Lautenschläger <sup>4</sup>, Stefan Schwaiger <sup>1,\*</sup>, Hermann Stuppner <sup>1</sup>, Stefania Marzocco <sup>3</sup>

<sup>1</sup> Institute of Pharmacy/Pharmacognosy, Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria

<sup>2</sup> University of Kimpa Vita, Province of Uíge, Rua Henrique Freitas No. 1, Bairro Popular, Uíge, Angola

<sup>3</sup> Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano SA, Italy

<sup>4</sup> Department of Biology, Institute of Botany, Faculty of Science, Technische Universität Dresden, 01062 Dresden, Germany

\* Corresponding author. Tel.: +43 51250758409. E-mail address: stefan.schwaiger@uibk.ac.at

## INDEX

<b>Spectroscopic data of compounds isolated .....</b>	<b>3</b>
<b>Phytochemical and pharmacological analysis of the most active fractions.....</b>	<b>8</b>
Figure S1. Cell viability of the obtained PE, DEE, PRC, EtOAc, 1-BuOH and H <sub>2</sub> O fractions.....	8
Figure S2. HPLC-UV chromatogram (205 nm) of DEE subfractions A–R after separation by NP-MPLC.....	9
Figure S3. Cell viability of DEE subfractions A–R of the methanolic extract of the subaerial parts of <i>C. articulatus</i> . .....	10
Figure S4. GC chromatogram and peak assignment of the PE fraction of the methanolic extract of the subaerial parts of <i>C. articulatus</i> . ....	11
Table S1. Antiproliferative activity and NO production inhibition of compounds <b>1–11</b> obtained from the PE fraction of the subaerial parts of <i>C. articulatus</i> . ....	12
Table S2. Antiproliferative activity of compounds <b>12–19</b> obtained from the DEE fraction of the subaerial parts of <i>C. articulatus</i> . ....	13
Figure S5. Comparison of the chromatograms (205 nm) of the HPLC-UV analysis of extract subfractions of <i>S.</i> <i>holoschoenus</i> and <i>C. articulatus</i> .....	14

## Spectroscopic data of compounds isolated

*Copa-3-en-2 $\alpha$ -ol (1)* [C<sub>15</sub>H<sub>24</sub>O]: White needles; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 24.2 (CHCl<sub>3</sub>; c 0.05); <sup>1</sup>H NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>H</sub> (in ppm) 5.36 (1H, dq, *J* = 3.1, 1.6 Hz, H-3), 4.32 (1H, brs, H-2), 2.19 (1H, ddd, *J* = 6.3, 3.5, 1.7 Hz, H-1), 1.84 (1H, brs, H-6), 1.76 (1H, m, H-9a), 1.72 (3H, t, *J* = 1.6 Hz, H-15), 1.63 (1H, m, H-8a), 1.61 (1H, m, H-7), 1.59 (1H, s, H-5), 1.59 (1H, m = H-9b), 1.53 (1H, m, H-8b), 1.52 (1H, m, H-11), 0.88 (3H, d, *J* = 3.2 Hz, H-13), 0.87 (3H, d, *J* = 3.2 Hz, H-12), 0.82 (3H, s, H-14). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>C</sub> (in ppm) 148.72 (C, C-4), 119.01 (CH, C-3), 70.74 (CH, C-2), 55.45 (CH, C-5), 48.80 (C, C-10), 44.60 (CH, C-7), 43.98 (CH, C-1), 41.73 (CH, C-6), 36.55 (CH<sub>2</sub>, C-9), 32.23 (CH, C-11), 22.87 (CH<sub>3</sub>, C-15), 21.88 (CH<sub>2</sub>, C-8), 20.15 (CH<sub>3</sub>, C-13), 19.66 (CH<sub>3</sub>, C-12), 19.11 (CH<sub>3</sub>, C-14). LC-ESI-MS (positive mode): *m/z* 203.1 [M+H-H<sub>2</sub>O]<sup>+</sup> (100), 405.2 [2M-2OH]<sup>+</sup> (84), 243.1 [M+Na]<sup>+</sup> (6).

*Caryophyllene oxide (2)* [C<sub>15</sub>H<sub>24</sub>O]: Colorless oil; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 26.0 (CHCl<sub>3</sub>; c 0.05); <sup>1</sup>H NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>H</sub> (in ppm) 4.98 (1H, s, H-13a), 4.86 (1H, s, H-13b), 2.88 (1H, dd, *J* = 10.6, 4.3 Hz, H-5), 2.62 (1H, dd, *J* = 19.4, 8.9 Hz, H-9), 2.34 (1H, ddd, *J* = 12.8, 8.2, 4.4 Hz, H-7a), 2.25 (1H, ddt, *J* = 12.4, 8.5, 4.3 Hz, H-6a), 2.12 (1H, m, H-7b), 2.09 (1H, dt, *J* = 12.3, 3.6 Hz, H-3a), 1.76 (1H, t, *J* = 9.8, H-1), 1.69 (1H, dd, *J* = 10.6, 8.3 Hz, H-10a), 1.64 (1H, m, H-2a), 1.62 (1H, m, H-10b), 1.42 (1H, m, H-2b), 1.33 (1H, dddd, *J* = 12.8, 10.7, 8.1, 4.5 Hz, H-6b), 1.20 (3H, s, H-12), 1.01 (3H, s, H-15), 0.98 (3H, s, H-14), 0.96 (1H, dd, *J* = 13.2, 5.0 Hz, H-3b). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>C</sub> (in ppm) 152.01 (C, C-8), 112.91 (CH<sub>2</sub>, C-13), 63.92 (CH, C-5), 60.00 (C, C-4), 50.89 (CH, C-1), 48.88 (CH, C-9), 39.90 (CH<sub>2</sub>, C-10), 39.30 (CH<sub>2</sub>, C-3), 34.17 (C, C-11), 30.34 (CH<sub>2</sub>, C-6), 30.03 (CH<sub>3</sub>, C-15), 29.93 (CH<sub>2</sub>, C-7), 27.35 (CH<sub>2</sub>, C-2), 21.76 (CH<sub>3</sub>, C-14), 17.14 (CH<sub>3</sub>, C-12). LC-ESI-MS (positive mode): *m/z* 221.2 [M+H]<sup>+</sup> (100), 441.3 [2M+H]<sup>+</sup> (6).

*Humulene epoxide-II (3)* [C<sub>15</sub>H<sub>24</sub>O]: Colorless oil; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 23.2 (CHCl<sub>3</sub>; c 0.1); <sup>1</sup>H NMR (600.19 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>H</sub> (in ppm) 5.28 (1H, ddd, *J* = 15.6, 10.1, 5.3 Hz, H-3), 5.15 (1H, d, *J* = 15.8 Hz, H-4), 5.00 (1H, dt, *J* = 9.2, 3.6 Hz, H-7), 2.57 (1H, dd, *J* = 12.4, 5.3 Hz, H-2a), 2.53 (1H, dd, *J* = 10.2, 3.9 Hz, H-11), 2.24 (1H, m, H-9a), 2.17 (1H, ddd, *J* = 16.7, 9.4, 4.8 Hz, H-10a), 2.11 (1H, dd, *J* = 12.2, 9.5, 5.2 Hz, H-9b), 1.99 (1H, dd, *J* = 13.7, 9.2 Hz, H-6a), 1.87 (1H, dd, *J* = 13.8, 5.9 Hz, H-6b), 1.64 (1H, dd, *J* = 12.5, 10.1 Hz, H-2b), 1.56 (3H, d, *J* = 4.2 Hz, H-15), 1.35 (1H, ddt, *J* = 13.2, 10.2, 5.1 Hz, H-10b), 1.30 (3H, s, H-12), 1.11 (3H, s, H-14), 1.08 (3H, s, H-13). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>C</sub> (in ppm) 143.28 (CH, C-4), 132.08 (C, C-8), 125.88 (CH, C-7), 122.25 (CH, C-3), 63.38 (C, C-1), 62.10 (CH, C-11), 42.73 (CH<sub>2</sub>, C-2), 40.37 (CH<sub>2</sub>, C-6), 36.77\* (CH<sub>2</sub>, C-9), 36.66\* (C, C-5), 29.15 (CH<sub>3</sub>, C-13), 25.61 (CH<sub>3</sub>, C-14), 24.89 (CH<sub>2</sub>, C-10), 17.34 (CH<sub>3</sub>, C-12), 15.23 (CH<sub>3</sub>, C-15). \*The assignments of C-5 and C-9 may be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode): *m/z* 221.2 [M+H]<sup>+</sup> (100), 441.2 [2M+H]<sup>+</sup> (13), 243.1 [M+Na]<sup>+</sup> (11).

*Mustakone (4)* [C<sub>15</sub>H<sub>22</sub>O]: Colorless oil; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 13.2 (MeOH; c 0.1); <sup>1</sup>H NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>H</sub> (in ppm) 5.74 (1H, q, *J* = 1.5 Hz, H-3), 2.68 (1H, dd, *J* = 6.9, 1.7 Hz, H-1), 2.67 (1H, d, *J* = 2.8 Hz, H-6), 2.00 (3H, d, *J* = 1.5 Hz, H-14), 1.98 (1H, dd, *J* = 6.7, 1.4 Hz, H-5), 1.88 (1H, m, H-9a), 1.76 (1H, m, H-8a), 1.72 (1H, m, H-9b), 1.63 (1H, s, H-7), 1.52 (2H, m, H-8b, H-11), 0.98 (3H, s, H-15), 0.86\* (3H, d, *J* = 6.7 Hz, H-12), 0.85\* (3H, d, *J* = 6.7 Hz, H-13). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta$ <sub>C</sub> (in ppm) 204.24 (C, C-2), 170.13 (C, C-4), 121.53 (CH, C-3), 57.44 (C, C-10), 56.68 (CH, C-5), 56.12 (CH, C-6), 54.65 (CH, C-1), 45.56 (CH, C-7), 36.84 (CH<sub>2</sub>, C-9), 31.91 (CH, C-11), 23.82 (CH<sub>3</sub>, C-14), 22.13 (CH<sub>2</sub>, C-8), 20.44 (CH<sub>3</sub>, C-15), 20.09 (CH<sub>3</sub>, C-12), 19.66 (CH<sub>3</sub>, C-13). \*The assignments of H-12 and H-13 may

be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode):  $m/z$  219.2  $[M+H]^+$  (100), 437.2  $[2M+H]^+$  (100), 459.3  $[2M+Na]^+$  (46).

*Kobusone (5)*  $[C_{14}H_{22}O_2]$ : White solid;  $[\alpha]_D^{20}$  - 95.0 (CHCl<sub>3</sub>;  $c$  0.1);  $^1H$  NMR (600.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 3.06 (1H, m, H-9), 2.70 (1H, dd,  $J$  = 10.1, 5.0 Hz, H-5), 2.55 (2H, m, H-7), 2.40 (1H, m, H-6a), 2.15 (1H, dt,  $J$  = 13.2, 3.7 Hz, H-3a), 2.07 (1H, t,  $J$  = 10.3 Hz, H-10a), 1.94 (1H, ddd,  $J$  = 10.6, 8.8, 1.3 Hz, H-1), 1.66 (2H, m, H-2, H-10b), 1.53 (1H, m, H-2), 1.45 (1H, dddd,  $J$  = 13.2, 10.1, 6.2, 4.8 Hz, H-6b), 1.31 (3H, s, H-14), 1.04 (3H, s, H-12), 1.03 (3H, s, H-13), 0.95 (1H, td,  $J$  = 13.3, 4.4 Hz, H-3b).  $^{13}C$  NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 214.39 (C, C-8), 61.84 (CH, C-5), 59.16 (C, C-4), 52.80 (CH, C-9), 51.49 (CH, C-1), 39.17 (CH<sub>2</sub>, C-3), 37.86 (CH<sub>2</sub>, C-7), 35.45 (CH<sub>2</sub>, C-10), 34.68 (C, C-11), 29.49 (CH<sub>3</sub>, C-13), 26.64 (CH<sub>2</sub>, C-2), 24.94 (CH<sub>2</sub>, C-6), 22.37 (CH<sub>3</sub>, C-12), 16.37 (CH<sub>3</sub>, C-14). LC-ESI-MS (positive mode):  $m/z$  223.0  $[M+H]^+$  (100), 245.1  $[M+Na]^+$  (10).

*Cyperotundone (6)*  $[C_{15}H_{22}O]$ : White solid;  $[\alpha]_D^{20}$  + 30.0 (MeOH;  $c$  0.1);  $^1H$  NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 2.59 (1H, dd,  $J$  = 18.9, 7.1 Hz, H-6a), 2.30 (1H, d,  $J$  = 19.0 Hz, H-6b), 2.17 (1H, m, H-10), 2.15 (1H, d,  $J$  = 17.4 Hz, H-2a), 2.01 (1H, d,  $J$  = 17.4 Hz, H-2b), 1.95 (2H, m, H-7, H-8a), 1.72 (3H, t,  $J$  = 1.4 Hz, H-14), 1.59 (1H, d,  $J$  = 13.6 Hz, H-9a), 1.41 (1H, dt,  $J$  = 13.0, 6.7, 3.5 Hz, H-8b), 1.10 (3H, s, H-12), 1.02 (1H, ddd,  $J$  = 12.5, 7.0, 2.0 Hz, H-9b), 0.74 (3H, s, H-13), 0.61 (3H, d,  $J$  = 6.4 Hz, H-15).  $^{13}C$  NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 211.18 (C, C-3), 181.91 (C, C-5), 133.54 (C, C-4), 58.85 (C, C-1), 45.51 (CH, C-7), 41.77 (C, C-11), 41.30 (CH<sub>2</sub>, C-2), 33.88 (CH, C-10), 30.64 (CH<sub>2</sub>, C-6), 28.52 (CH<sub>2</sub>, C-9), 27.16 (CH<sub>2</sub>, C-8), 24.97 (CH<sub>3</sub>, C-13), 19.71 (CH<sub>3</sub>, C-12), 16.97 (CH<sub>3</sub>, C-15), 8.47 (CH<sub>3</sub>, C-14). LC-ESI-MS (positive mode):  $m/z$  219.1  $[M+H]^+$  (100), 459.3  $[2M+Na]^+$  (38).

*Humulene dioxide (7)*  $[C_{15}H_{24}O_2]$ : Colorless needles;  $[\alpha]_D^{20}$  - 25.8 (CHCl<sub>3</sub>;  $c$  0.1);  $^1H$  NMR (600.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 5.49 (1H, ddd,  $J$  = 15.6, 10.6, 5.0 Hz, H-3), 5.31 (1H, d,  $J$  = 16.5 Hz, H-4), 2.73 (1H, dd,  $J$  = 10.1, 5.0 Hz, H-11), 2.64 (1H, dd,  $J$  = 12.2, 5.0 Hz, H-2a), 2.48 (1H, d,  $J$  = 9.6 Hz, H-7), 2.20 (1H, tt,  $J$  = 13.8, 5.3 Hz, H-10a), 2.13 (1H, ddd,  $J$  = 13.6, 5.8, 2.4 Hz, H-9a), 1.65 (1H, t,  $J$  = 11.5 Hz, H-2b), 1.61 (1H, d,  $J$  = 14.3 Hz, H-6a), 1.37 (2H, m, H-6b, H-10b), 1.31 (6H, s, H-12, H-15), 1.20 (3H, s, H-14), 1.08 (3H, s, H-13), 1.08 (1H, m, H-9b).  $^{13}C$  NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 143.03 (CH, C-4), 122.72 (CH, C-3), 64.81 (CH, C-7), 63.51 (C, C-1), 60.46 (CH, C-11), 60.23 (C, C-8), 43.45 (CH<sub>2</sub>, C-2), 38.50 (CH<sub>2</sub>, C-6), 35.79 (C, C-5), 34.99 (CH<sub>2</sub>, C-9), 30.82 (CH<sub>3</sub>, C-13), 25.33 (CH<sub>2</sub>, C-10), 23.50 (CH<sub>3</sub>, C-14), 16.60\* (CH<sub>3</sub>, C-12), 16.56\* (CH<sub>3</sub>, C-15). \*The assignments of C-12 and C-15 may be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode):  $m/z$  237.2  $[M+H]^+$  (100), 259.1  $[M+Na]^+$  (76), 275.0  $[M+K]^+$  (9); LC-ESI-MS (negative mode):  $m/z$  235.7  $[M-H]^-$  (100).

*Humulene dioxide (8)*  $[C_{15}H_{24}O_2]$ : Colorless needles;  $[\alpha]_D^{20}$  - 13.8 (CHCl<sub>3</sub>;  $c$  0.1);  $^1H$  NMR (600.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 5.56 (1H, d,  $J$  = 15.9 Hz, H-4), 5.53 (1H, dd,  $J$  = 8.0, 4.3 Hz, H-3), 2.69 (1H, d,  $J$  = 10.9 Hz, H-7), 2.63 (1H, d,  $J$  = 9.2 Hz, H-11), 2.61 (1H, dd,  $J$  = 12.8, 3.3 Hz, H-2a), 2.23 (1H, dt,  $J$  = 13.9, 3.8 Hz, H-9a), 1.99 (1H, dt,  $J$  = 14.7, 4.1 Hz, H-10a), 1.81 (1H, dd,  $J$  = 13.5, 7.9 Hz, H-2b), 1.72 (1H, m, H-6a), 1.46 (2H, m, H-6b, H-10b), 1.39 (3H, s, H-12), 1.29 (1H, m, H-9b), 1.20 (3H, s, H-14), 1.18 (3H, s, H-15), 1.10 (3H, s, H-13).  $^{13}C$  NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 142.59 (CH, C-4), 123.94 (CH, C-3), 64.15 (C, C-1), 63.16 (2CH, C-7, C-11), 60.76 (C, C-8), 42.49 (CH<sub>2</sub>, C-6), 40.83 (CH<sub>2</sub>, C-2), 36.93 (CH<sub>2</sub>, C-9), 34.68 (C, C-5), 30.25 (CH<sub>3</sub>, C-13), 26.95 (CH<sub>3</sub>, C-14), 23.68 (CH<sub>2</sub>, C-10), 19.14

(CH<sub>3</sub>, C-12), 16.47 (CH<sub>3</sub>, C-15). LC-ESI-MS (positive mode):  $m/z$  237.2 [M+H]<sup>+</sup> (100), 259.1 [M+Na]<sup>+</sup> (46); LC-ESI-MS (negative mode):  $m/z$  235.9 [M-H]<sup>-</sup> (100).

(-)-*Guaia-1(10),11-dien-9-one* (**9**) [C<sub>15</sub>H<sub>22</sub>O]: Colorless needles; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 49.0 (CHCl<sub>3</sub>; *c* 0.1); <sup>1</sup>H NMR (600.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 4.73 (2H, d, *J* = 8.9 Hz, H-12), 2.83 (1H, m, H-5), 2.72 (1H, dd, *J* = 13.6, 12.2 Hz, H-8a), 2.57 (1H, m, H-2a), 2.53 (1H, dd, 13.9, 3.3 Hz, H-8b), 2.49 (1H, dd, *J* = 8.0, 4.3 Hz, H-7), 2.39 (1H, dt, *J* = 18.6, 7.2 Hz, H-2b), 2.28 (1H, p, *J* = 6.7 Hz, H-4), 1.82 (1H, m, H-3a), 1.77 (3H, d, *J* = 1.7 Hz, H-14), 1.75 (3H, s, H-13), 1.72 (1H, m, H-6a), 1.52 (2H, dddd, *J* = 13.9, 12.4, 7.2, 5.0 Hz, H-6b, H-3b), 0.89 (3H, d, *J* = 7.1 Hz, H-15). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 204.53 (C, C-9), 163.22 (C, C-1), 148.43 (C, C-11), 131.39 (C, C-10), 109.72 (CH<sub>2</sub>, C-12), 46.76 (CH<sub>2</sub>, C-8), 45.06 (CH, C-5), 39.66 (CH, C-7), 38.82 (CH, C-4), 32.57 (CH<sub>2</sub>, C-2), 31.71 (CH<sub>2</sub>, C-3), 31.47 (CH<sub>2</sub>, C-6), 21.20 (CH<sub>3</sub>, C-13), 14.83 (CH<sub>3</sub>, C-14), 14.54 (CH<sub>3</sub>, C-15). LC-ESI-MS (positive mode):  $m/z$  219.0 [M+H]<sup>+</sup> (100), 459.2 [M+Na]<sup>+</sup> (47).

*Muurolane-2 $\beta$ ,9 $\beta$ -diol-3-ene* (**10**) [C<sub>15</sub>H<sub>26</sub>O<sub>2</sub>]: White powder; [ $\alpha$ ]<sub>D</sub><sup>20</sup> - 73.0 (CHCl<sub>3</sub>; *c* 0.1); <sup>1</sup>H NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 5.76 (1H, dd, *J* = 5.6, 1.5 Hz, H-5), 3.95 (1H, brs, H-3), 2.32 (1H, brs, H-6), 1.94 (1H, pd, *J* = 6.9, 3.1 Hz, H-11), 1.80 (3H, brs, H-15), 1.74 (3H, m, H-1, H-2), 1.56 (1H, m, H-9a), 1.39 (3H, m, H-8, H-9b), 1.22 (3H, s, H-14), 1.19 (1H, m, H-7), 0.89 (3H, d, *J* = 6.9 Hz, H-12), 0.85 (3H, d, *J* = 6.9 Hz, H-13). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 134.21 (C, C-4), 129.86 (CH, C-5), 72.18 (C, C-10), 68.62 (CH, C-3), 42.72 (CH, C-7), 40.37 (CH, C-1), 34.90\* (CH, C-6), 34.83\* (CH<sub>2</sub>, C-9), 30.69 (CH<sub>2</sub>, C-2), 29.45 (CH<sub>3</sub>, C-14), 27.21 (CH, C-11), 21.67 (CH<sub>3</sub>, C-12), 21.18 (CH<sub>3</sub>, C-15), 19.28 (CH<sub>2</sub>, C-8), 15.60 (CH<sub>3</sub>, C-13). \*The assignments of C-6 and C-9 may be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode):  $m/z$  239.1 [M+H]<sup>+</sup> (100), 261.1 [M+Na]<sup>+</sup> (37), 499.2 [2M+Na]<sup>+</sup> (51); LC-ESI-MS (negative mode):  $m/z$  237.1 [M-H]<sup>-</sup> (100).

*Corymbolone* (**11**) [C<sub>15</sub>H<sub>24</sub>O<sub>2</sub>]: White powder; [ $\alpha$ ]<sub>D</sub><sup>20</sup> + 18.6 (CHCl<sub>3</sub>; *c* 0.1); <sup>1</sup>H NMR (400.19 MHz, CDCl<sub>3</sub>)  $\delta_H$  (in ppm) 4.74 (2H, s, H-12), 2.66 (1H, ddd, *J* = 16.2, 10.0, 3.6 Hz, H-2a), 2.42 (1H, m, H-2b), 2.39 (1H, m, H-6a), 2.32 (1H, tt, *J* = 12.6, 3.5 Hz, H-7), 1.89 (2H, m, H-3a, H-9a), 1.86 (1H, m, H-4), 1.75 (3H, s, H-13), 1.68 (2H, m, H-6b, H-8a), 1.60 (1H, m, H-3b), 1.43 (1H, dd, *J* = 13.8, 3.8, 2.1 Hz, H-9b), 1.37 (1H, ddd, *J* = 13.7, 4.0, 1.2 Hz, H-8b), 1.24 (3H, d, *J* = 0.8 Hz, H-14), 1.19 (3H, d, *J* = 7.5 Hz, H-15). <sup>13</sup>C NMR (150.91 MHz, CDCl<sub>3</sub>)  $\delta_C$  (in ppm) 215.96 (C, C-1), 149.69 (C, C-11), 109.04 (CH<sub>2</sub>, C-12), 78.75 (C, C-5), 51.38 (C, C-10), 40.73 (CH, C-4), 39.50 (CH, C-7), 37.38 (CH<sub>2</sub>, C-9), 34.39 (CH<sub>2</sub>, C-2), 30.33 (CH<sub>2</sub>, C-3), 28.17 (CH<sub>2</sub>, C-6), 25.52 (CH<sub>2</sub>, C-8), 21.26 (CH<sub>3</sub>, C-13), 20.52 (CH<sub>3</sub>, C-14), 17.90 (CH<sub>3</sub>, C-15). LC-ESI-MS (positive mode):  $m/z$  237.2 [M+H]<sup>+</sup> (100); LC-ESI-MS (negative mode):  $m/z$  235.8 [M-H]<sup>-</sup> (100).

*p*-Hydroxybenzoic acid (**12**) [C<sub>7</sub>H<sub>6</sub>O<sub>3</sub>]: Yellowish-white solid; <sup>1</sup>H NMR (600.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 7.87 (2H, d, *J* = 8.7 Hz, H-2, H-6), 6.81 (2H, d, *J* = 8.7 Hz, H-3, H-5). <sup>13</sup>C NMR (150.91 MHz, MeOH-*d*<sub>4</sub>) δ<sub>C</sub> (in ppm) 170.84 (C, C-7), 163.07 (C, C-4), 132.92 (2CH, C-2, C-6), 123.66 (C, C-1), 115.93 (2CH, C-3, C-5). LC-ESI-MS (negative mode): *m/z* 137.0 [M-H]<sup>-</sup> (100), 275.1 [2M-H]<sup>-</sup> (30).

*trans*-*p*-Hydroxycinnamic acid (**13**) [C<sub>9</sub>H<sub>8</sub>O<sub>3</sub>]: White solid; <sup>1</sup>H NMR (600.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 7.58 (1H, d, *J* = 15.9 Hz, H-7), 7.45 (2H, d, *J* = 8.6 Hz, H-2, H-6), 6.81 (2H, d, *J* = 8.8 Hz, H-3, H-5), 6.29 (1H, d, *J* = 15.9 Hz, H-8). <sup>13</sup>C NMR (150.91 MHz, MeOH-*d*<sub>4</sub>) δ<sub>C</sub> (in ppm) 171.51 (C, C-9), 161.06 (C, C-4), 146.13 (CH, C-7), 131.00 (2CH, C-2, C-6), 127.40 (C, C-1), 116.79 (2CH, C-3, C-5), 116.34 (CH, C-8). LC-ESI-MS (positive mode): *m/z* 165.1 [M+H]<sup>+</sup> (100); LC-ESI-MS (negative mode): *m/z* 163.0 [M-H]<sup>-</sup> (100).

2*R*/2*S* Dihydroluteolin (**14**) [C<sub>15</sub>H<sub>12</sub>O<sub>6</sub>]: Yellowish-white solid; [α]<sub>D</sub><sup>20</sup> - 4.2 (MeOH; *c* 0.1); <sup>1</sup>H NMR (600.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 6.95 (1H, d, *J* = 1.7 Hz, H-6'), 6.82 (2H, s, H-2', H-5'), 5.92 (1H, brs, H-8), 5.90 (1H, d, *J* = 2.1 Hz, H-6), 5.31 (1H, dd, *J* = 12.7, 3.1 Hz, H-2), 3.10 (1H, dd, *J* = 17.1, 12.7 Hz, H-3a), 2.73 (1H, dd, *J* = 17.1, 3.1 Hz, H-3b). <sup>13</sup>C NMR (150.91 MHz, MeOH-*d*<sub>4</sub>) δ<sub>C</sub> (in ppm) 197.66 (C, C-4), 168.78\*<sup>1</sup> (C, C-7), 165.45 (C, C-5), 164.88\*<sup>1</sup> (C, C-9), 146.92 (C, C-4'), 146.54 (C, C-3'), 131.85 (C, C-1'), 119.24 (CH, C-2'), 116.26 (CH, C-5'), 114.71 (CH, C-6'), 103.26 (C, C-10), 97.17\*<sup>2</sup> (CH, C-6), 96.31\*<sup>2</sup> (CH, C-8), 80.50 (CH, C-2), 44.12 (CH<sub>2</sub>, C-3). \*<sup>1,2</sup> The assignments of C-7 and C-9 and of C-6 and C-8 may be exchangeable and are labeled with an asterisk. LC-ESI-MS (negative mode): *m/z* 287.0 [M-H]<sup>-</sup> (100), 575.0 [2M-H]<sup>-</sup> (57).

4*S*/4*R*-4-Hydroxy-1,10-*seco*-muurol-5-ene-1,10-dione (**15**) [C<sub>15</sub>H<sub>24</sub>O<sub>3</sub>]: Colorless oil; [α]<sub>D</sub><sup>20</sup> + 0.9 (MeOH; *c* 0.1); <sup>1</sup>H NMR (400.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 6.48 (1H, s, H-5), 2.61 (1H, ddd, *J* = 17.0, 6.3, 5.3 Hz, H-2a), 2.46 (1H, ddd, *J* = 17.0, 9.2, 6.1 Hz, H-2b), 2.29 (2H, t, *J* = 7.4 Hz, H-9), 2.28 (1H, t, *J* = 7.4 Hz, H-7), 2.13 (3H, brs, H-14), 2.10 (2H, brs, H-3), 1.92 (1H, m, H-8a), 1.73 (1H, ddt, *J* = 13.2, 7.9, 6.6 Hz, H-11), 1.62 (1H, ddt, *J* = 13.9, 11.4, 7.0 Hz, H-8b), 1.43 (3H, s, H-15), 0.92 (3H, d, *J* = 6.7 Hz, H-12), 0.80 (3H, d, *J* = 6.7 Hz, H-13). <sup>13</sup>C NMR (150.91 MHz, MeOH-*d*<sub>4</sub>) δ<sub>C</sub> (in ppm) 211.80 (C, C-10), 200.92 (C, C-1), 153.01 (CH, C-5), 139.94 (C, C-6), 69.30 (C, C-4), 45.19 (CH, C-7), 42.38 (CH<sub>2</sub>, C-9), 37.80 (CH<sub>2</sub>, C-3), 36.24 (CH<sub>2</sub>, C-2), 32.76 (CH, C-11), 29.90 (CH<sub>3</sub>, C-14), 27.41 (CH<sub>3</sub>, C-15), 25.97 (CH<sub>2</sub>, C-8), 21.19 (CH<sub>3</sub>, C-13), 20.79 (CH<sub>3</sub>, C-12). LC-ESI-MS (positive mode): *m/z* 235.1 [M+H-H<sub>2</sub>O]<sup>+</sup> (100); LC-ESI-MS (negative mode): *m/z* 297.2 [M-H+FA]<sup>-</sup> (100).

Piceatannol (**16**) [C<sub>14</sub>H<sub>12</sub>O<sub>4</sub>]: White powder; <sup>1</sup>H NMR (400.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 6.97 (1H, d, *J* = 1.9 Hz, H-2), 6.89 (1H, d, *J* = 16.2 Hz, H-7), 6.83 (1H, dd, *J* = 8.2, 1.9 Hz, H-6), 6.74 (1H, d, *J* = 16.1 Hz, H-8), 6.73 (1H, d, *J* = 8.2 Hz, H-5), 6.43 (2H, d, *J* = 2.1 Hz, H-10, H-14), 6.15 (1H, t, *J* = 2.1 Hz, H-12). <sup>13</sup>C NMR (150.91 MHz, MeOH-*d*<sub>4</sub>) δ<sub>C</sub> (in ppm) 159.64 (2C, C-11, C-13), 146.53 (C, C-3), 146.49 (C, C-4), 141.29 (C, C-9), 131.05 (C, C-1), 129.69 (CH, C-7), 126.99 (CH, C-8), 120.18 (CH, C-6), 116.41 (CH, C-5), 113.81 (CH, C-2), 105.74 (2CH, C-10, C-14), 102.62 (CH, C-12). LC-ESI-MS (positive mode): *m/z* 245.1 [M+H]<sup>+</sup> (100); LC-ESI-MS (negative mode): *m/z* 243.1 [M-H]<sup>-</sup> (100), 478.1 [2M-H]<sup>-</sup> (18).

*trans*-Scirpusin B (**17**) [C<sub>28</sub>H<sub>22</sub>O<sub>8</sub>]: Yellowish-brownish solid; [α]<sub>D</sub><sup>20</sup> - 18.2 (MeOH; *c* 0.1); <sup>1</sup>H NMR (400.19 MHz, MeOH-*d*<sub>4</sub>) δ<sub>H</sub> (in ppm) 6.77 (1H, d, *J* = 16.2 Hz, H-7b), 6.76 (1H, d, *J* = 2.4 Hz, H-2a), 6.74 (1H, d, *J* = 8.3 Hz, H-5a), 6.70 (1H, d, *J* = 1.9 Hz, H-2b), 6.64 (2H, d, *J* = 8.2 Hz, H-5b, H-6a), 6.62 (1H, d, *J* = 2.1 Hz, H-14b), 6.58 (1H, dd,


$J = 9.0, 2.7$  Hz, H-6b), 6.54 (1H, d,  $J = 16.3$  Hz, H-8b), 6.26 (1H, d,  $J = 2.0$  Hz, H-12b), 6.18 (1H, t-like, H-12a), 6.16 (1H, s, H-10a), 6.15 (1H, s, H-14a), 5.28 (1H, d,  $J = 5.8$  Hz, H-7a), 4.34 (1H, d,  $J = 5.8$  Hz, H-8a).  $^{13}\text{C}$  NMR (150.91 MHz, MeOH- $d_4$ )  $\delta_{\text{C}}$  (in ppm) 162.86 (C, C-11b), 159.97 (2C, C-11a, C-13a), 159.76 (C, C-13b), 147.66 (C, C-9a), 146.61<sup>\*1</sup> (C, C-4b), 146.50<sup>\*1</sup> (C, C-3b), 146.42<sup>\*2</sup> (C, C-4a), 146.31<sup>\*2</sup> (C, C-3a), 137.03 (C, C-9b), 134.96 (C, C-1a), 130.99<sup>\*3</sup> (C, C-1b), 130.90<sup>\*3</sup> (CH, C-7b), 123.65 (CH, C-8b), 120.03 (CH, C-6b), 119.84 (C, C-10b), 118.46 (CH, C-6a), 116.45 (CH, C-5b), 116.27 (CH, C-5a), 114.08 (CH, C-2b), 113.66 (CH, C-2a), 107.33 (2CH, C-10a, C-14a), 104.43 (CH, C-14b), 102.24 (CH, C-12a), 96.82 (CH, C-12b), 94.90 (CH, C-7a), 58.12 (CH, C-8a). <sup>\*1,2</sup> The assignments of C-3b and C-4b, of C-3a and C-4a and of C-1b and C-7b may be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode):  $m/z$  487.1  $[\text{M}+\text{H}]^+$  (100); LC-ESI-MS (negative mode):  $m/z$  485.1  $[\text{M}-\text{H}]^-$  (100), 971.1  $[\text{2M}-\text{H}]^-$  (70).

*trans-Sobrerol* (**18**) [ $\text{C}_{10}\text{H}_{18}\text{O}_2$ ]: White solid;  $[\alpha]_{\text{D}}^{20} - 4.4$  ( $\text{CHCl}_3$ ;  $c$  0.1);  $^1\text{H}$  NMR (400.19 MHz, MeOH- $d_4$ )  $\delta_{\text{H}}$  (in ppm) 5.57 (1H, d,  $J = 5.4$  Hz, H-6), 3.98 (1H, dd,  $J = 4.0, 2.2$  Hz, H-2), 2.12 (1H, m, H-5a), 1.97 (1H, dd,  $J = 13.9, 2.2$  Hz, H-3a), 1.80 (1H, s, H-5b), 1.77 (4H, s, H-4, H-10), 1.37 (1H, m, H-3b), 1.18 (6H, s, H-8, H-9).  $^{13}\text{C}$  NMR (150.91 MHz, MeOH- $d_4$ )  $\delta_{\text{C}}$  (in ppm) 135.41 (C, C-1), 126.17 (CH, C-6), 72.78 (C, C-7), 69.25 (CH, C-2), 39.76 (CH, C-4), 34.18 ( $\text{CH}_2$ , C-3), 28.04 ( $\text{CH}_2$ , C-5), 27.12 ( $\text{CH}_3$ , C-9), 26.94 ( $\text{CH}_3$ , C-8), 21.15 ( $\text{CH}_3$ , C-10). LC-ESI-MS (positive mode):  $m/z$  193.1  $[\text{M}+\text{Na}]^+$  (10).

*Cyperusphenol B* (**19**) [ $\text{C}_{42}\text{H}_{32}\text{O}_{12}$ ]: Brownish solid;  $[\alpha]_{\text{D}}^{20} - 17.6$  (MeOH;  $c$  0.1);  $^1\text{H}$  NMR (400.19 MHz, acetone- $d_6$ )  $\delta_{\text{H}}$  (in ppm) 6.84 (1H, d,  $J = 2.4$  Hz, H-14a), 6.76 (1H, d,  $J = 1.8$  Hz, H-2a), 6.74<sup>\*1</sup> (1H, d,  $J = 2.1$  Hz, H-2c), 6.72<sup>\*1</sup> (1H, d,  $J = 8.1$  Hz, H-5a), 6.69 (1H, dd,  $J = 8.3, 1.9$  Hz, H-6a), 6.66 (1H, d,  $J = 8.1$  Hz, H-5c), 6.56 (1H, dd,  $J = 8.2, 2.1$  Hz, H-6c), 6.50 (1H, s, H-5b), 6.41 (1H, d,  $J = 2.3$  Hz, H-12a), 6.39 (1H, d,  $J = 1.9$  Hz, H-14b), 6.27 (1H, brs, H-7a), 6.22 (2H, d,  $J = 2.2$  Hz, H-10c, H-14c), 6.12 (1H, t,  $J = 2.1$  Hz, H-12c), 6.07 (1H, s, H-2b), 5.99 (1H, d,  $J = 1.9$  Hz, H-12b), 4.65 (1H, d,  $J = 11.2$  Hz, H-7b), 4.29 (1H, brs, H-8a), 4.01 (1H, d,  $J = 3.7$  Hz, H-7c), 3.67 (1H, dd,  $J = 11.4, 3.8$  Hz, H-8c), 3.56 (1H, dd,  $J = 12.0, 11.7$  Hz, H-8b).  $^{13}\text{C}$  NMR (150.91 MHz, acetone- $d_6$ )  $\delta_{\text{C}}$  (in ppm) 159.48 (C, C-13b), 159.34 (2C, C-11c, C-13c), 158.95 (C, C-11a), 157.90 (C, C-11b), 156.78 (C, C-13a), 151.38 (C, C-9c), 145.54<sup>\*2</sup> (C, C-3a), 145.51<sup>\*2</sup> (C, C-4a), 145.64<sup>\*2</sup> (C, C-3c), 143.93<sup>\*2</sup> (C, C-3b), 143.76<sup>\*2</sup> (2C, C-4b, C-4c), 142.68 (C, C-9a), 140.70 (C, C-1c), 137.96 (C, C-1b), 137.76 (C, C-9b), 135.00 (C, C-1a), 130.98 (C, C-6b), 124.46 (C, C-10b), 120.03 (CH, C-6c), 117.62 (CH, C-6a), 117.14 (CH, C-5b), 116.49 (C, C-10a), 116.06 (2CH, C-5a, C-2c), 115.63 (CH, C-5c), 113.19 (CH, C-2a), 112.53 (CH, C-2b), 106.92 (CH, C-14b), 106.82 (2CH, C-10c, C-14c), 103.63 (CH, C-14a), 101.74 (CH, C-12a), 101.18 (CH, C-12c), 95.10 (CH, C-12b), 84.94 (CH, C-7a), 55.53 (CH, C-7c), 55.02 (CH, C-8c), 52.06 (CH, C-8a), 51.20 (CH, C-8b), 43.16 (CH, C-7b). <sup>\*1,2</sup> The assignments of H-5a and H-2c and of C-3a, C-4a, C-3b, C-4b, C-3c and C-4c may be exchangeable and are labeled with an asterisk. LC-ESI-MS (positive mode):  $m/z$  729.2  $[\text{M}+\text{H}]^+$  (100); LC-ESI-MS (negative mode):  $m/z$  727.2  $[\text{M}-\text{H}]^-$  (100).

## Phytochemical and pharmacological analysis of the most active fractions


Figure S1. Cell viability of the obtained PE, DEE, PRC, EtOAc, 1-BuOH and H<sub>2</sub>O fractions.



The MTT activity is expressed as relative percentage to that in the untreated group. LPS-stimulated J774A.1 murine macrophages were incubated with methanol extract and its subfractions (petroleum ether, diethyl ether, precipitate, ethyl acetate, 1-butanol and water) at concentrations of 100, 50, 25 and 12.5  $\mu\text{g mL}^{-1}$ , followed by measurement of the cell viability vs LPS  $\pm$  SEM ( $n=3$ ). 6-MP was used as positive control (PC) at a concentration of 1  $\mu\text{M}$ .




Figure S2. HPLC-UV chromatogram (205 nm) of DEE subfractions A–R after separation by NP-MPLC.




All fractions were tested for their pharmacological profile and fractions E, F, H, M, N, and P were selected for further examination.

Figure S3. Cell viability of DEE subfractions A–R of the methanolic extract of the subaerial parts of *C. articulatus*.



The MTT activity is expressed as relative percentage to that in the untreated group. LPS-stimulated J774A.1 murine macrophages were incubated with subfractions (A–R) at concentrations of 5, 1 and 0.1 µg mL<sup>-1</sup>, followed by measurement of the cell viability vs LPS ± SEM (n=3). 6-MP was used as positive control (PC) at a concentration of 1 µM

Figure S4. GC chromatogram and peak assignment of the PE fraction of the methanolic extract of the subaerial parts of *C. articulatus*.



For GC conditions see **4.2** (General experimental methods).

Table S1. Antiproliferative activity and NO production inhibition of compounds **1–11** obtained from the PE fraction of the subaerial parts of *C. articulatus*.

PE compound	Antiproliferative activity (% activity $\pm$ SEM vs LPS)			NO production (% inhibition $\pm$ SEM vs LPS)		
	20 $\mu$ M	10 $\mu$ M	5 $\mu$ M	20 $\mu$ M	10 $\mu$ M	5 $\mu$ M
<b>1</b>	23.50 $\pm$ 3.50	8.00 $\pm$ 0.00	7.50 $\pm$ 2.50	35.00 $\pm$ 0.00	20.00 $\pm$ 2.00	11.50 $\pm$ 0.50
<b>2</b>	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	10.50 $\pm$ 0.50	8.50 $\pm$ 2.50	0.00 $\pm$ 0.00
<b>3</b>	12.50 $\pm$ 4.50	9.50 $\pm$ 0.50	0.50 $\pm$ 0.50	17.50 $\pm$ 0.50	17.50 $\pm$ 5.50	0.00 $\pm$ 0.00
<b>4</b>	17.50 $\pm$ 2.50	14.50 $\pm$ 2.50	5.50 $\pm$ 2.50	28.50 $\pm$ 0.50	27.00 $\pm$ 0.00	3.00 $\pm$ 0.00
<b>5</b>	17.50 $\pm$ 1.50	12.50 $\pm$ 0.00	0.50 $\pm$ 2.50	32.00 $\pm$ 0.00	30.50 $\pm$ 0.50	6.50 $\pm$ 0.50
<b>6</b>	3.50 $\pm$ 0.30	1.50 $\pm$ 0.10	0.50 $\pm$ 0.50	18.50 $\pm$ 2.50	16.00 $\pm$ 2.00	3.00 $\pm$ 3.00
<b>7</b>	4.50 $\pm$ 0.40	1.00 $\pm$ 0.00	0.00 $\pm$ 0.00	31.50 $\pm$ 3.50	22.00 $\pm$ 0.00	3.00 $\pm$ 3.00
<b>9</b>	13.50 $\pm$ 0.60	11.50 $\pm$ 0.50	2.50 $\pm$ 0.50	32.00 $\pm$ 1.00	25.00 $\pm$ 1.00	8.50 $\pm$ 1.50
<b>10</b>	16.00 $\pm$ 0.20	14.50 $\pm$ 0.05	0.50 $\pm$ 0.73	21.50 $\pm$ 4.50	11.50 $\pm$ 6.50	6.50 $\pm$ 0.50
<b>11</b>	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	21.50 $\pm$ 0.50	13.50 $\pm$ 0.50	14.00 $\pm$ 0.00
<b>positive control</b>	<b>1 <math>\mu</math>M</b>			<b>1 <math>\mu</math>M</b>		
6-MP	47.33 $\pm$ 1.85					
L-NAME				44.00 $\pm$ 0.50		


Inhibition assays vs LPS  $\pm$  SEM (n=3) at concentrations of 20, 10 and 5  $\mu$ M.

Table S2. Antiproliferative activity of compounds **12–19** obtained from the DEE fraction of the subaerial parts of *C. articulatus*.

DEE compound	Antiproliferative activity (% activity $\pm$ SEM vs LPS)		
	10 $\mu$ M	5 $\mu$ M	1 $\mu$ M
<b>12</b>	2.83 $\pm$ 0.33	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>13</b>	18.50 $\pm$ 0.50	10.33 $\pm$ 0.33	7.67 $\pm$ 0.67
<b>14</b>	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>15</b>	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>16</b>	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00	0.00 $\pm$ 0.00
<b>17</b>	2.50 $\pm$ 0.01	1.90 $\pm$ 0.33	0.00 $\pm$ 0.00
<b>18</b>	35.00 $\pm$ 0.01	24.00 $\pm$ 0.56	12.00 $\pm$ 0.10
<b>19</b>	3.00 $\pm$ 0.33	2.67 $\pm$ 0.67	2.33 $\pm$ 0.33
<b>positive control</b>	<b>1 <math>\mu</math>M</b>		
6-MP	46.54 $\pm$ 0.35		
L-NAME			

Inhibition assays vs LPS  $\pm$  SEM (n=3) at concentrations of 10, 5 and 1  $\mu$ M.

Figure S5. Comparison of the chromatograms (205 nm) of the HPLC-UV analysis of extract subfractions of *S. holoschoenus* and *C. articulatus*.



HPLC-UV chromatogram (205 nm) of the DEE fraction of the methanolic rhizomes and roots extract after DCM extraction of *S. holoschoenus* vs. the PRC fraction of the methanolic rhizome and root extract of *C. articulatus*.